According to Tongbi Finance, data from Qichacha shows that based on the announcement of the bidding results for the project &#34;Research on the Drugability of Class I Small Molecule Drugs and IND Package - Oral Administration (Screening &amp; Supporting NMPA &amp; FDA Phase I Clinical Trial Application),&#34; Shanghai Medicilon Inc. announced on June 5, 2026, that it won the procurement project of Shenzhen GeBiJia Molecular Drug Innovation Center Co., Ltd., with a winning amount of 9.1785 million yuan.
Related listed company: Medicilon (688202.SH)
Tongbi Finance Tip:
Medicilon (688202.SH) had an operating income of 1.163 billion yuan in 2025, with an operating income growth rate of 12.08%. The net profit attributable to the parent company was -168 million yuan, with a net profit growth rate of 49.27%. The return on net assets was -8.26%.
In the first quarter of 2026, the company's operating income was 365 million yuan, with an operating income growth rate of 36.52%. The net profit attributable to the parent company was 16 million yuan, with a net profit growth rate of 207.35%.
The company currently belongs to the healthcare industry, with main product types including chemical reagents, biological diagnostic reagents, and pharmaceutical distribution. The main business composition in the 2025 report was preclinical research: 50.72%; drug discovery and pharmaceutical research: 49.27%; other businesses: 0.01%.

688202

Medicilon announced that it won the bid for the procurement project of Shenzhen GeBiJia Molecular Drug Innovation Center Co., Ltd., with a bid amount of 9.1785 million yuan. The project involves research on the drugability of Class I small molecule drugs and IND Package

同壁财经

Medicilon

Medicilon (688202): Won the procurement project of Shenzhen GeBiJia Molecular Drug Innovation Center Co., Ltd., with a winning amount of 9.1785 million yuan